Meeting everyday challenges: antipsychotic therapy in the real world.

作者: Philip Gorwood

DOI: 10.1016/J.EURONEURO.2006.06.002

关键词: AntipsychoticAnxietyPsychiatryClinical psychologyClinical trialSchizophreniaTolerabilitySubstance abusePopulationPsychologyAripiprazole

摘要: Patients with schizophrenia and their physicians face a number of challenges, such as long-term control symptoms, maintaining cognitive function subjective well-being, preventing relapse. While randomised, placebo-controlled trials open-label extensions can provide valuable information about the efficacy tolerability newer antipsychotic agents, they cannot address all variables that may affect treatment outcome. Factors function, side effects, patients' attitudes to medication well being results in real-life clinical practice. Moreover, patient cohorts enrolled are often not reflective wider population schizophrenia. For example, patients conditions anxiety panic disorders or comorbid substance abuse, those severe illness from certain ethnic age groups, be excluded trials. In addition, themselves refuse participate studies because fear under-treated. Naturalistic are, therefore, an important means providing additional data on safety effectiveness agents 'real-world' settings. Studies Clinical Antipsychotic Trials Intervention Effectiveness (CATIE) study, Schizophrenia Outpatient Health Outcomes (SOHO) study Broad Trial Aripiprazole (BETA) studies, together large-scale database analyses, now producing supplementary observed long-term, extension studies. Such naturalistic will continue real-world atypical antipsychotics respect key outcomes continuation prolonged recovery.

参考文章(25)
T. S. Stroup, J. P. McEvoy, M. S. Swartz, M. J. Byerly, I. D. Glick, J. M. Canive, M. F. McGee, G. M. Simpson, M. C. Stevens, J. A. Lieberman, The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project: Schizophrenia Trial Design and Protocol Development Schizophrenia Bulletin. ,vol. 29, pp. 15- 31 ,(2003) , 10.1093/OXFORDJOURNALS.SCHBUL.A006986
M Kungel, M Ebrecht, S Modell, C Werner, T Spevakné-Göröcs, Effects of long-term (up to 5 years) open-label treatment with aripiprazole Pharmacopsychiatry. ,vol. 38, ,(2005) , 10.1055/S-2005-918754
Joseph Peuskens, Caroline Demily, Florence Thibaut, Treatment of cognitive dysfunction in schizophrenia Clinical Therapeutics. ,vol. 27, ,(2005) , 10.1016/J.CLINTHERA.2005.07.015
Stephen M. Stahl, Does evidence from clinical trials in psychopharmacology apply in clinical practice The Journal of Clinical Psychiatry. ,vol. 62, pp. 6- 7 ,(2001) , 10.4088/JCP.V62N0102
Del D. Miller, Atypical Antipsychotics: Sleep, Sedation, and Efficacy The Primary Care Companion To The Journal of Clinical Psychiatry. ,vol. 6, pp. 3- 7 ,(2004)
Martin Dossenbach, Cesar Arango-Dávila, Hernan Silva Ibarra, Eric Landa, Jaime Aguilar, Osvaldo Caro, Joanna Leadbetter, Sheila Assunção, Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. The Journal of Clinical Psychiatry. ,vol. 66, pp. 1021- 1030 ,(2005) , 10.4088/JCP.V66N0810
Alex Hofer, Martina Hummer, Regina Huber, Martin Kurz, Thomas Walch, W. Wolfgang Fleischhacker, Selection bias in clinical trials with antipsychotics. Journal of Clinical Psychopharmacology. ,vol. 20, pp. 699- 702 ,(2000) , 10.1097/00004714-200012000-00019
Siegfried Kasper, Martin Brecher, Lesley Fitton, Andrew Martin Jones, Maintenance of long-term efficacy and safety of quetiapine in the open-label treatment of schizophrenia. International Clinical Psychopharmacology. ,vol. 19, pp. 281- 289 ,(2004) , 10.1097/01.YIC.0000138822.62874.FD
Dwight Dickinson, Virginia N Iannone, Christopher M Wilk, James M Gold, General and specific cognitive deficits in schizophrenia. Biological Psychiatry. ,vol. 55, pp. 826- 833 ,(2004) , 10.1016/J.BIOPSYCH.2003.12.010